Clinical Trials
11 trialsNCT00354276 2014-01-10
VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00112554 2013-11-06
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 3 Completed
NCT00282022 2013-11-06
VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025129 2013-07-18
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT00049686 2013-07-18
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 1 Completed
NCT00049699 2013-07-18
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00070538 2013-07-18
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
National Cancer Institute (NCI)
Phase 1 Completed
NCT00083187 2013-07-18
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00098436 2013-07-18
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
National Cancer Institute (NCI)
Phase 1 Completed
NCT00304005 2013-07-18
VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00840684 2011-05-13
Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed